| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
021-61312847; 18021002903 |
| Email: |
3008007409@qq.com |
| Products Intro: |
Product Name:Pacmilimab (anti-PD-L1)
CAS:2145091-51-4
Purity:ExactAb?, Validated, Carrier Free, Low Endotoxin, Azide Free Package:100μg Remarks:K14080
|
| Company Name: |
ShangHai Biochempartner Co.,Ltd
|
| Tel: |
177-54423994 17754423994 |
| Email: |
2853530910@QQ.com |
| Products Intro: |
Product Name:Pacmilimab
CAS:2145091-51-4
Purity:95% Package:100ug;500ug;1mg
|
| Company Name: |
Guangzhou Hongyuan Chemical Co.,Ltd
|
| Tel: |
15817493340 |
| Email: |
981810490@qq.com |
| Products Intro: |
Product Name:Pacmilimab
CAS:2145091-51-4
Purity:95% Package:1mg;1g;100g
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 15002144251 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:Pacmilimab
CAS:2145091-51-4
Purity:95% Package:1mg/RMB 2150;5mg/RMB 5630;10mg/RMB 7630
|
|
| | Pacmilimab Basic information |
| Product Name: | Pacmilimab | | Synonyms: | Pacmilimab;Research Grade Pacmilimab(DHJ70105);Research Grade Pacmilimab;Pacmilimab (anti-PD-L1) | | CAS: | 2145091-51-4 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Pacmilimab Structure]() |
| | Pacmilimab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Pacmilimab Usage And Synthesis |
| Uses | Pacmilimab (CX-072) is a potent PD-L1 inhibitor. Pacmilimab shows antitumor activity[1]. | | in vivo | Pacmilimab induces antitumor responses comparable to those of the same dose of the parental antibody in mice bearing MC38 tumors[1].
Pacmilimab accumulates in murine PD-L1-expressing tumors with minimal uptake in peripheral, non-cancerous lymphoid tissue, consistent with limited uptake in non-tumor PD-L1-expressing tissues and protection against autoimmunity[1].
| | References | [1] Naing A, et al. CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study. J Immunother Cancer. 2021 Jul;9(7):e002447. DOI:10.1136/jitc-2021-002447 |
| | Pacmilimab Preparation Products And Raw materials |
|